DAG-LA and DAG-DHLA Derivatives for Lipid Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutraceuticals and food additives are inadequate in effectively addressing obesity, diabetes, atherosclerosis, and oxidative stress, as they lack the necessary solubility and stability in fats and oils, and do not provide comprehensive health benefits.
Innovation Solution
Derivatives of diacylglycerol (DAG) esterified with alpha-lipoic acid (LA) and dihydro-alpha-lipoic acid (DHLA) are developed, enhancing solubility and stability, offering synergistic effects for health benefits and extended shelf life as antioxidants, stabilizers, and emulsifiers in food and pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nutraceuticals are used, then health benefits are provided, but solubility and stability in fats and oils are insufficient
Solution Approach 1:
The patent creates composite molecules by conjugating lipoic acid (LA) and dihydrolipoic acid (DHLA) with diacylglycerol (DAG) backbone structures. This composite approach combines the antioxidant properties of LA/DHLA with the metabolic benefits and lipid solubility of DAG, achieving both improved solubility in fats and oils while maintaining stability and health benefits
Solution Approach 2:
The patent modifies the chemical structure parameters of conventional nutraceuticals by esterifying LA and DHLA with DAG at specific positions (1, 2, or 3). This structural parameter change enhances lipophilicity and stability without compromising the biological activity, allowing the compounds to effectively address obesity, diabetes, and oxidative stress
2Adaptability or versatility
If conventional food additives are used, then basic food functionality is maintained, but comprehensive health benefits are not achieved
Solution Approach 1:
The DAG-LA and DAG-DHLA derivatives exhibit multiple functions simultaneously: they act as antioxidants (scavenging free radicals), metabolic regulators (improving insulin sensitivity and fat metabolism), and stabilizers (preventing lipid oxidation). This multi-functionality allows a single substance to provide comprehensive health benefits including obesity prevention, diabetes management, and cardiovascular protection
Solution Approach 2:
The patent merges the metabolic advantages of DAG (enhanced fat oxidation, reduced fat storage) with the antioxidant and metabolic benefits of LA/DHLA (mitochondrial function improvement, cholesterol management). This combination creates a synergistic effect where the compounds work together to address multiple lifestyle-related diseases more effectively than individual substances
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DAG-LA and DAG-DHLA derivatives demonstrate improved solubility and antioxidant properties, effectively preventing and treating obesity, diabetes, atherosclerosis, and oxidative stress, while extending the shelf life of food and pharmaceutical products.
Implementation Method 1
The synergistic effect of DAG and LA/DHLA of the invention are contemplated to be effective in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases
Implementation Method 2
Derivatives of diacylglycerol (DAG) esterified with alpha-lipoic acid (LA) and dihydro-alpha-lipoic acid (DHLA) are developed
Data Source
AI summary
Novel compounds, and in particular to diacylglycerol (1, 3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases.